Baricitinib: Can I use it even if I don’t have a medical diagnosis but I have patchy hair loss?

Baricitinib is a medication that has gained attention in recent years since its approval for severe alopecia areata, a condition that causes hair loss in defined patches. However, using it without a proper medical diagnosis and confirmation of the disease can lead to significant consequences and health risks. In this article, we will break down what baricitinib is, how it works, what the most relevant scientific research says, and why it is essential to consult a specialist before taking this type of medication—especially if you only have patchy hair loss without a formal diagnosis.

What is Baricitinib and what role does it play in treating hair loss?

Baricitinib is a drug that belongs to a group called Janus kinase (JAK) inhibitors. These JAK enzymes are proteins inside the body that help transmit signals between cells to regulate processes such as inflammation and immune system response. When these enzymes are overactive, they can cause autoimmune problems, where the body mistakenly attacks its own tissues. Baricitinib works by blocking these enzymes, thus reducing inflammation and abnormal immune system activity. Originally, this medication was approved to treat autoimmune diseases such as rheumatoid arthritis, where the immune system attacks the joints. In 2022, the United States Food and Drug Administration (FDA) expanded the indication of baricitinib to treat severe alopecia areata in adults. **This condition is an autoimmune disease that causes the immune system to attack hair follicles, leading to hair loss in visible patches, sometimes leaving completely bald areas **

Is all patchy hair loss alopecia areata? Why does diagnosis matter so much?

Hair loss in specific areas can be very worrying and confusing. However, this symptom does not always indicate alopecia areata. There are many causes that can lead to patchy hair loss, and each requires a different treatment approach. These include scalp infections caused by fungi, non-autoimmune inflammatory conditions, severe stress, nutritional deficiencies, side effects of medications, and even behavioral disorders like trichotillomania, which is the compulsive pulling of hair. For this reason, a rigorous medical diagnosis, made by a dermatologist or hair health specialist, is crucial before starting any treatment with powerful medications like baricitinib. A proper diagnosis usually involves a detailed clinical history, physical examination, sometimes blood tests, skin biopsies, or microbiological studies to rule out infections.

Is it safe and advisable to use Baricitinib if I don’t have a medical diagnosis but have patchy hair loss?

Using baricitinib without a medical diagnosis and professional supervision is neither safe nor advisable. Although it may seem like a quick and effective solution for hair loss, this medication has strong immunosuppressive effects that can carry serious health risks. Its FDA label carries a boxed warning for serious infections including tuberculosis, death from any cause, cancer, heart attack and stroke, and blood clots. It may harm an unborn baby, live vaccines should be avoided, and it can raise liver enzymes and interact with other medications. For these reasons, it is approved in the US only for adults with a confirmed diagnosis of severe alopecia areata, and doctors weigh these risks for each patient.

Scientific evidence: Studies and results on Baricitinib for alopecia areata treatment

The evidence behind the use of baricitinib in alopecia areata comes mainly from controlled clinical trials. The main study was published in 2022 in the *New England Journal of Medicine. It reported two randomized, double-blind, placebo-controlled trials (BRAVE-AA1 and BRAVE-AA2) that together included 1,200 adults with a confirmed diagnosis of severe alopecia areata. Participants received baricitinib 2 mg, 4 mg or placebo once daily for 36 weeks (about 9 months). The evaluation was conducted using scales that measure the amount of hair lost and regrown, with improvement observed through photographs and standardized clinical assessments.

At week 36, 36-39% on 4 mg and 19-23% on 2 mg reached 80% or more scalp coverage, compared with 3-6% on placebo.

Limits of the study: It is important to note that only people with a clinically confirmed diagnosis were evaluated. The use of the medication in people with patchy hair loss without diagnosis or in mild or intermittent cases was not explored. Longer follow-up to 104 weeks has since been published for people who stayed on treatment (Senna et al., 2024), but it too included only people with a confirmed diagnosis. Therefore, results cannot be extrapolated to people who have not undergone a diagnostic process.

Risks of self-medicating with Baricitinib: What can happen if I use it without medical supervision?

Baricitinib is a potent medication that must be managed under strict medical supervision. Using it without control can cause serious problems. Serious risks named on the label include serious infections such as tuberculosis, blood clots in the legs or lungs, changes in blood cell counts and raised liver enzymes. In the alopecia trials, the most frequent side effects were milder ones, such as upper respiratory infections, headache and acne. It can also interact with other medications, increasing risks. These risks make it essential that a doctor performs a complete evaluation before, during, and after treatment to monitor for potential complications. The first and most important step is to see a specialist, preferably a dermatologist, who can provide an accurate diagnosis and differentiate the causes of hair loss. In addition to the clinical exam, complementary tests such as blood work to detect vitamin deficiencies or autoimmune diseases, cultures to rule out infections, or even scalp biopsies might be required.

This will allow a clear diagnosis and help avoid unnecessary or potentially harmful treatments.

Depending on the cause, the doctor can recommend specific treatments ranging from nutritional supplements and lifestyle changes to topical therapies or medications like baricitinib in carefully selected cases.

User Experiences

Baricitinib (marketed as Olumiant) has been approved by the FDA for the treatment of severe alopecia areata, an autoimmune condition characterized by patchy hair loss. This medication functions as a Janus kinase (JAK) inhibitor, targeting specific enzymes to reduce inflammation and promote hair regrowth. Community feedback from individuals using Baricitinib for alopecia areata reveals a spectrum of experiences, highlighting both the potential benefits and considerations associated with the treatment.

One user shared their journey after taking baricitinib for four months at a dose set by their doctor (the approved doses are 2 mg and 4 mg once daily), noting significant hair regrowth on the scalp, eyebrows, and eyelashes. They mentioned initial side effects like headaches and oily skin, which subsided over time. Regular blood tests were conducted to monitor their health during the treatment. Another individual, who had been dealing with alopecia for two years, reported minor hair regrowth after a year on Baricitinib. They expressed joy over the appearance of stray hairs, emphasizing the emotional impact of even minimal progress. A 32-year-old male with stress-related alopecia areata described a 90% hair regrowth after starting Baricitinib 4mg. He attributed his success to a combination of the medication and lifestyle changes, including reduced stress and improved diet. He reported no significant side effects and highlighted the importance of patience during treatment.

Conversely, some users experienced less favorable outcomes. One person reported a relapse after 2.5 years on Baricitinib, with a significant return of hair loss. They said they then added minoxidil under their doctor's care. Another user faced challenges with medication adherence, leading to their doctor discontinuing the prescription due to inconsistent dosing. This individual expressed fear of hair loss returning and emphasized the importance of following the prescribed regimen. In summary, community members describe varied results with baricitinib for alopecia areata, often particularly when used under medical supervision and as part of a comprehensive treatment plan. However, responses vary, and potential side effects and the importance of adherence to the treatment regimen should be carefully considered.

Conclusion: Can I use Baricitinib if I don’t have a medical diagnosis but have patchy hair loss?

The answer is no. Baricitinib should not be used without a formal medical diagnosis and proper professional evaluation. Patchy hair loss can result from many different causes, and treatment should only start after identifying the specific cause. Using baricitinib without supervision can be dangerous due to its side effects and immunological risks. If you are facing hair loss, the best course of action is to seek medical attention, obtain an accurate diagnosis, and discuss treatment options, and their risks, with a professional.

References

King, B., Ohyama, M., Kwon, O., et al. (2022). Two phase 3 trials of baricitinib for alopecia areata. New England Journal of Medicine, 386(18), 1687–1699. https://doi.org/10.1056/NEJMoa2110343 https://www.nejm.org/doi/full/10.1056/NEJMoa2110343

U.S. Food & Drug Administration. (2022, June 13). FDA approves first systemic treatment for alopecia areata. https://www.fda.gov/news-events/press-announcements/fda-approves-first-systemic-treatment-alopecia-areata

U.S. Food & Drug Administration. (2022). OLUMIANT (baricitinib) tablets, for oral use: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207924s007lbl.pdf Senna M, Mostaghimi A, Ohyama M, et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. J Eur Acad Dermatol Venereol. 2024;38(3):583-593. https://pubmed.ncbi.nlm.nih.gov/38391212/

U.S. National Library of Medicine. OLUMIANT (baricitinib) tablets, prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=866e9f35-9035-4581-a4b1-75a621ab55cf

Allure. (2022, June 13). The FDA Has Approved Olumiant for the Treatment of Alopecia Areata. Retrieved from https://www.allure.com/story/fda-approves-olumiant-alopecia-treatment

Reddit. (2025, March 4). I've been taking Baricitinib (3.4mg) for 4 months and this is the difference. Retrieved from https://www.reddit.com/r/alopecia_areata/comments/1j3a2ue

Reddit. (2024, April 5). My hair is finally looking like it could come back 🙏. Retrieved from https://www.reddit.com/r/alopecia_areata/comments/1bw50m6

Reddit. (2023, November 22). Starting Baricitinib soon, any advice welcome :). Retrieved from https://www.reddit.com/r/alopecia_areata/comments/18183d8

Reddit. (2024, September 5). Baricitinib relapse. Any experiences with this that can be shared?. Retrieved from https://www.reddit.com/r/alopecia_areata/comments/1f98ykq

Reddit. (2024, December 4). Doctor refused to continue treatment. Retrieved from https://www.reddit.com/r/alopecia_areata/comments/1h65vu3